AI-based Clinical Trials Solution Provider Market Size Report, 2024-2033
The global AI-based clinical trials solution provider market size was exhibited at USD 2.60 billion in 2023 and is projected to hit around USD 19.16 billion by 2033, growing at a CAGR of 22.11% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 3.17 Billion |
| Market Size by 2033 | USD 19.16 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 22.11% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Clinical Trial Phase, Therapeutic Application, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Unlearn.AI, Inc.; Saama Technologies; Antidote Technologies, Inc.; Phesi; Deep 6 AI; Innoplexus; Mendel.ai; Intelligencia; Median Technologies; Symphony AI; BioAge Labs, Inc.; AiCure, LLC; CONSILX; DEEP LENS AI; Halo Health Systems; Pharmaseal; Ardigen; Trials.Ai; Koneksa Health; Euretos; BioSymetrics; Google- Verily; GNS Healthcare; IBM Watson; Exscientia |
The increasing adoption of AI-based platforms to improve the productivity and efficacy of trials at various stages is driving the market for AI-based clinical trial solution providers. Also, the supportive initiatives by the private and public sectors for different therapeutic areas are some of the factors propelling the market growth. Furthermore, the rising awareness and diversified applications provided by AI in the field of clinical trials such as designing drug trials, improved patient selection, site selection, patient monitoring, etc. is bolstering the market growth.
The utilization of AI in drug trials can be useful to improve the cost, clinical outcomes, and time required for drug trials, as drug development is a cost-intensive and time-consuming process. For instance, in January 2020, Recursion Pharma and Takeda entered into a research collaboration for rare diseases, which resulted in the evaluation of preclinical and clinical molecules in over 60 unique indications in less than 18 months. Moreover, AI can also be used to reduce the bias in medical data. For instance, Genentech collaborated with Stanford University to use an open-source AI system to fight and reduce bias in drug trials. In addition, due to the shifting trend from traditional practices to technology-based approaches, major pharmaceutical companies are highly implementing AI-based technologies in clinical trials, thereby boosting the market growth.
Furthermore, the rising penetration of AI in drug trials and the availability of AI-based solutions can help in different aspects of clinical trials such as drug trial design, patient enrichment & enrollment, investigator and site selection, patient monitoring, medication adherence, and many more, which is boosting the growth of the market for AI-based clinical trial solution providers. Patient eligibility and enrollment are some of the important steps for the success of the overall drug trial and as per research, 85% of the drug trials are delayed during patient recruitment, and 30% are terminated early due to recruitment failure. AI-based platforms are proving to be beneficial in reducing this hurdle. Hence, many researchers are using AI for the drug trial process, thereby fostering the growth of the market for AI-based clinical trial solution providers.
In addition, the COVID-19 outbreak led to the rise in the utilization of AI-based technologies. Increasing adoption of technologically advanced solutions for drug discovery and development and recruited patient data analysis are some of the factors responsible for the increase in penetration of AI-based drug development and drug trial solutions. The pharmaceutical companies, CROs, and academia shifted their focus from the traditional drug development process to the AI-based solution to improve the clinical outcomes and for the minimization of cost and time required for the drug trials. Also, the decentralized drug trials witnessed a boost as many trials were on hold due to COVID-19, due to which many key players turned toward the collection of patient data available.
The phase-II segment dominated the market for AI-based clinical trial solution providers and accounted for a revenue share of 46.1% in 2023, owing to the presence of a large number of registered clinical trials active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the drug trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase.
In addition, Phase I is anticipated to register the fastest growth rate of 24.2% during the forecast period. The adoption of AI-based solutions is anticipated to increase, as their utilization since phase I can be beneficial for patient recruitment, retention, and better trial design. Also, these platforms can develop unique patient-centric endpoints and collect real-world data, thereby impelling the adoption of these solutions in phase-I.
The oncology segment accounted for the highest revenue share of 22.4% in 2023. The high prevalence of cancer across the globe and a large number of drug trials in the field of oncology is contributing to the adoption of AI-enabled technologies. Also, a large number of players are developing and adopting oncology-based AI tools for clinical trials, thereby propelling the segment growth. For instance, in January 2023, Hematology-Oncology Associates of Central New York and Deep Lens partnered for the expansion of a drug trial program, wherein The VIPER provided by Deep Lens will be used to identify the qualified patients for clinical trials by pre-screening all patients.
In addition, cardiovascular disease is anticipated to register the fastest growth rate of 25.6% during the forecast period owing to the rising prevalence of CVD across the globe. Also, the improving drug trials and increasing penetration of AI-based platforms for the analysis of cardiovascular diseases with a new approach are major factors contributing to the segment growth.
In 2023, based on end-use, the pharmaceutical companies segment accounted for the highest revenue share of 66.2%. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers to identify the new drug target, and the overall process of drug development and clinical trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendors for leveraging the AI technology for R&D and the overall drug discovery process, thereby, impelling the growth. For instance, in April 2020, Vir Biotechnology and GSK signed an agreement to boost the drug discovery for COVID-19 by utilizing CRISPR and AI.
However, the others is anticipated to register the fastest growth rate of 25.0% during the forecast period owing to the rising trend of adoption of AI-enabled solutions by Contract Research Organizations, government agencies, etc. The rising participation of CROs and other organizations in the development and adoption of AI-based platforms and technologies, useful in drug discovery and development, along with clinical trials, is anticipated to boost the growth of the market for AI-based clinical trial solution providers during the forecast period.
North America dominated the global AI-based clinical trials solution providers market and accounted for a revenue share of 44.7% in 2023. It is attributed to the presence of a number of AI-based start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Furthermore, the growing awareness of AI-based technologies and their adoption to enhance the drug trial outcome is impelling market growth in the region. The supportive government initiatives and increasing strategic initiatives by major players are among a few factors that are driving the demand for AI-based clinical trial solutions in the region.
However, in Asia Pacific, the market for AI-based clinical trial solution providers is anticipated to register the fastest growth rate of 30.0% over the forecast period due to the rising penetration of AI-based tools and favorable government initiatives for the adoption of AI in different healthcare fields. Recruitment for clinical trials is increasing in Asia as compared to North America and Europe. This is due to the presence of a large patient pool and low trial cost. Furthermore, as per Novotech’s CEO, Asia Pacific is now recognized by clinical phase biotechnology firms for accelerated patient enrollment, especially in infectious diseases, oncology, metabolic conditions, immune-oncology, and rare diseases as well as low cost of clinical research combined with experienced investigators and research teams.
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global AI-based clinical trials solution provider market.
Clinical Trial Phase
Therapeutic Application
End-user
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers